PE20240138A1 - Formas cristalinas de un compuesto farmaceutico - Google Patents
Formas cristalinas de un compuesto farmaceuticoInfo
- Publication number
- PE20240138A1 PE20240138A1 PE2023001212A PE2023001212A PE20240138A1 PE 20240138 A1 PE20240138 A1 PE 20240138A1 PE 2023001212 A PE2023001212 A PE 2023001212A PE 2023001212 A PE2023001212 A PE 2023001212A PE 20240138 A1 PE20240138 A1 PE 20240138A1
- Authority
- PE
- Peru
- Prior art keywords
- crystalline forms
- pharmaceutical compound
- crystalline form
- crystalline
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000010577 Niemann-Pick disease type C Diseases 0.000 abstract 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 150000002305 glucosylceramides Chemical class 0.000 abstract 1
- 150000002339 glycosphingolipids Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invencion provee una forma cristalina del compuesto (I) que es una base libre cristalina y exhibe una o mas reflexiones, indicadas como valor 2 theta, a 17,2 ± 0,2°C, 17,8 ± 0,2°C, 21,2 ± 0,2° y 22,4 ± 0,2°C, en un patron de difraccion de rayos X en polvo; tiene un punto de fusion de 89°C a 96°C y es sustancialmente no higroscopica. Tambien se refiere a una composicion farmaceutica que lo comprende y a un proceso para preparar dicha forma cristalina; siendo util en el el tratamiento de una enfermedad que involucra niveles anormales de glucosilceramida y/o niveles elevados de glucoesfingolipidos, tal como la enfermedad de Niemann-Pick tipo C.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20199934.9A EP3978474A1 (en) | 2020-10-02 | 2020-10-02 | Crystalline forms of a pharmaceutical compound |
PCT/EP2021/077100 WO2022069709A1 (en) | 2020-10-02 | 2021-10-01 | Crystalline forms of a pharmaceutical compound |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20240138A1 true PE20240138A1 (es) | 2024-01-30 |
Family
ID=72744696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023001212A PE20240138A1 (es) | 2020-10-02 | 2021-10-01 | Formas cristalinas de un compuesto farmaceutico |
Country Status (19)
Country | Link |
---|---|
US (1) | US20240287001A9 (es) |
EP (3) | EP3978474A1 (es) |
JP (2) | JP2023524169A (es) |
KR (2) | KR102659466B1 (es) |
CN (1) | CN116390910A (es) |
AU (2) | AU2021353055B2 (es) |
BR (2) | BR122022018214A2 (es) |
CA (1) | CA3193939C (es) |
CL (1) | CL2023000943A1 (es) |
DK (1) | DK4114826T3 (es) |
ES (1) | ES2964105T3 (es) |
FI (1) | FI4114826T3 (es) |
IL (1) | IL301882A (es) |
MA (1) | MA58885B1 (es) |
MX (1) | MX2023003618A (es) |
PE (1) | PE20240138A1 (es) |
TW (1) | TW202229236A (es) |
WO (1) | WO2022069709A1 (es) |
ZA (1) | ZA202310184B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4209215A1 (en) * | 2022-01-10 | 2023-07-12 | Azafaros B.V. | Treatment of gm2 gangliosidosis |
IL314212A (en) * | 2022-01-10 | 2024-09-01 | Azafaros B V | Treatment of GM2 gangliosidosis |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3461812T3 (da) | 2014-03-27 | 2021-12-20 | Acad Medisch Ct | N-(5-(biphen-4-ylmethyloxy)pentyl)-substituerede iminosukre som inhibitorer af glucosylceramidsyntase |
US20190195897A1 (en) * | 2015-06-24 | 2019-06-27 | Universiteit Leiden | Glycosylated metabolites |
-
2020
- 2020-10-02 EP EP20199934.9A patent/EP3978474A1/en not_active Withdrawn
-
2021
- 2021-10-01 WO PCT/EP2021/077100 patent/WO2022069709A1/en active Application Filing
- 2021-10-01 DK DK21798287.5T patent/DK4114826T3/da active
- 2021-10-01 TW TW110136766A patent/TW202229236A/zh unknown
- 2021-10-01 FI FIEP21798287.5T patent/FI4114826T3/fi active
- 2021-10-01 US US18/029,842 patent/US20240287001A9/en active Pending
- 2021-10-01 AU AU2021353055A patent/AU2021353055B2/en active Active
- 2021-10-01 MA MA58885A patent/MA58885B1/fr unknown
- 2021-10-01 EP EP21798287.5A patent/EP4114826B1/en active Active
- 2021-10-01 IL IL301882A patent/IL301882A/en unknown
- 2021-10-01 BR BR122022018214-3A patent/BR122022018214A2/pt not_active Application Discontinuation
- 2021-10-01 CA CA3193939A patent/CA3193939C/en active Active
- 2021-10-01 KR KR1020237014953A patent/KR102659466B1/ko active IP Right Grant
- 2021-10-01 EP EP23191550.5A patent/EP4295847A3/en active Pending
- 2021-10-01 BR BR112022018020-9A patent/BR112022018020B1/pt active IP Right Grant
- 2021-10-01 PE PE2023001212A patent/PE20240138A1/es unknown
- 2021-10-01 KR KR1020247012671A patent/KR20240056628A/ko active Application Filing
- 2021-10-01 JP JP2022577645A patent/JP2023524169A/ja active Pending
- 2021-10-01 CN CN202180067242.0A patent/CN116390910A/zh active Pending
- 2021-10-01 MX MX2023003618A patent/MX2023003618A/es unknown
- 2021-10-01 ES ES21798287T patent/ES2964105T3/es active Active
-
2022
- 2022-12-20 AU AU2022291486A patent/AU2022291486B2/en active Active
-
2023
- 2023-03-30 CL CL2023000943A patent/CL2023000943A1/es unknown
- 2023-10-30 ZA ZA2023/10184A patent/ZA202310184B/en unknown
-
2024
- 2024-02-02 JP JP2024015037A patent/JP2024054192A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20240138A1 (es) | Formas cristalinas de un compuesto farmaceutico | |
BR112021009595A2 (pt) | Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres | |
CO2019004137A2 (es) | 1,2,4–triazolonas 2,4,5–trisustituidas | |
CO2017007679A2 (es) | Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1 | |
NI201700011A (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
CL2019001369A1 (es) | Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo. | |
CU20170077A7 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende | |
CU20150096A7 (es) | Compuestos de amida y composición farmacéutica para el tratamiento de vih | |
UY36665A (es) | Derivados de ciclohexano sustituidos con amidas | |
GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
SA520411524B1 (ar) | مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها | |
CO2018005842A2 (es) | Composición farmacéutica que comprende un potente inhibidor de urat 1 | |
GT201200004A (es) | Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria | |
CO2020007018A2 (es) | Proceso para preparar tapinarof | |
CL2017002354A1 (es) | Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd. | |
AR128459A2 (es) | Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación | |
DOP2017000107A (es) | Diamino-quinoleina 2,4 sustituida como nuevos agentes anticancerigenos | |
CR20190144A (es) | Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos | |
CO2019011546A2 (es) | Compuestos y métodos para el tratamiento de enfermedades parasitarias | |
CO2019011547A2 (es) | Compuesto sólido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol | |
CR20180368A (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
DOP2016000161A (es) | Ureas asimétricas p- sustituidas y usos médicos de las mismas. | |
CL2019001004A1 (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos. | |
CU20190095A7 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias |